LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

Accueil・Liste d'Actions・Merck & Co Inc.

Merck & Co Inc.

Fermé

Secteur Soins de santé

103.73 -0.47

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

103.7

Max

105.05

Chiffres clés
By Trading Economics
Revenu	693M 5.5B
Ventes	310M 16B
P/E Moyenne du Secteur	137.56 112.16
BPA	2.28
Marge bénéficiaire	33.861
Employés	72,000
EBITDA	491M 7.4B

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+31.51 upside

Dividendes
By Dow Jones
Prochains Résultats	31 oct. 2024
Date du Prochain Dividende	6 janv. 2025
Date du Prochain Détachement de Dividende	12 déc. 2024

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-9.4B 278B
Ouverture précédente	104.2
Clôture précédente	103.73

Sentiment de l'Actualité

By Acuity

29%

71%

94 / 389 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

103.86 / 109.69 Support & Résistance

Merck & Co Inc. Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

23 oct. 2024, 14:04 UTC

Acquisitions, Fusions, Rachats

Merck Buys Yale Cancer-Therapy Spinout Modifi Biosciences

9 août 2024, 11:14 UTC

Acquisitions, Fusions, Rachats

Merck Buying Drug Targeting B-Cell Diseases for Up to $1.3 Billion

30 juil. 2024, 14:00 UTC

Résultats

Trending: Merck 2Q Profit Beats Expectations; Fiscal Year Adjusted EPS Outlook Lowered

30 juil. 2024, 11:17 UTC

Résultats

Merck Swings to 2Q Profit Ahead of Views, Lowers FY24 Adjusted EPS Outlook

24 oct. 2024, 13:50 UTC

Acquisitions, Fusions, Rachats

This Biotech Stock Could Rocket 800%, Analyst Says -- Barrons.com

3 oct. 2024, 19:02 UTC

Acquisitions, Fusions, Rachats

CEOs Are on the Hunt for More M&A. Where the Next Deals Are. -- Barrons.com

3 oct. 2024, 18:20 UTC

Acquisitions, Fusions, Rachats

CEOs Are on the Hunt for More M&A. Where the Next Deals Are. -- Barrons.com

1 oct. 2024, 10:46 UTC

Acquisitions, Fusions, Rachats

Merck to Post 3Q Charge of About 28c/Share on Curon Deal >MRK

1 oct. 2024, 10:46 UTC

Acquisitions, Fusions, Rachats

Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, From Curon Biopharmaceutical

30 sept. 2024, 21:02 UTC

Actualités

FOMO on China Stock Rally? Think Twice About Buying In. -- Barrons.com

12 sept. 2024, 15:02 UTC

Actualités

Moderna Cost Cuts Fail to Restore Investor Trust -- Heard on the Street -- WSJ

12 sept. 2024, 10:00 UTC

Actualités

Moderna Pulls Back on R&D and Delays Timeline for Profitability -- Barrons.com

9 sept. 2024, 17:55 UTC

Actualités

A Better Drug Than Merck's Blockbuster Keytruda? Not So Fast -- WSJ

9 sept. 2024, 09:17 UTC

Actualités

Merck Stock Falls After Rival Beats Keytruda Cancer Drug in Trial -- Barrons.com

3 sept. 2024, 17:22 UTC

Actualités

Pfizer Better Watch Out for This Biotech -- Heard on the Street-- WSJ

12 août 2024, 14:30 UTC

Acquisitions, Fusions, Rachats

Correction to Big Drugmakers Are Clinching Smaller Deals Article -- WSJ

12 août 2024, 09:30 UTC

Actualités

Acquisitions, Fusions, Rachats

Big Drugmakers Are Clinching Smaller Deals -- WSJ

1 août 2024, 15:56 UTC

Résultats

Merck Created the World's Biggest Drug. Now It -2-

1 août 2024, 15:56 UTC

Résultats

Merck Created the World's Biggest Drug. Now It Has to Replace It. -- Barrons.com

30 juil. 2024, 15:53 UTC

Résultats

Nasdaq Dives As Microsoft Earnings Loom; Two Dow Jones Leaders Crater On Earnings (Live Updates) -- IBD

30 juil. 2024, 15:28 UTC

Market Talk

Résultats

Merck's Keytruda Continues to See Growth in U.S., Abroad -- Market Talk

30 juil. 2024, 13:45 UTC

Résultats

Trending: Merck 2Q Profit Beats Expectations; FY Adj EPS Outlook Lowered

30 juil. 2024, 10:45 UTC

Résultats

Merck Beats Profit And Sales Expectations Amid Keytruda Strength, But Provides Mixed Full-Year Outlook -- MarketWatch

30 juil. 2024, 10:32 UTC

Résultats

Merck Revised 2024 Adjusted EPS View Includes 51c/Share Charge on EyeBio Deal >MRK

30 juil. 2024, 10:31 UTC

Résultats

Merck 2Q Sales Rose 11% Ex-Forex >MRK

30 juil. 2024, 10:31 UTC

Résultats

Merck Posts Stronger-Than-Expected Results, But Outlook Falls Short -- IBD

30 juil. 2024, 10:30 UTC

Résultats

Merck 2Q Keytruda Sales Up 16% >MRK

30 juil. 2024, 10:30 UTC

Résultats

Merck 2Q Pharmaceutical Sales $14.41B >MRK

30 juil. 2024, 10:30 UTC

Résultats

Merck 2Q Keytruda Sales $7.27B >MRK

30 juil. 2024, 10:30 UTC

Résultats

Merck 2Q Gardasil/Gardasil 9 Sales Up 1% >MRK

Comparaison

Variation de prix

Merck & Co Inc. prévision

Objectif de Prix

By TipRanks

31.51% hausse

Prévisions sur 12 Mois

Moyen 137.07 USD 31.51%

Haut 155 USD

Bas 115 USD

Basé sur 20 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

20 ratings

Achat

Maintien

Vente

Basé sur 20 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

103.86 / 109.69Support & Résistance

All events are bearish.

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

94 / 389Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Merck & Co Inc.

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species.